The FDA has put a partial hold on Biosciences’ seizure study application over preclinical toxicity data and concerns about ...

Teva has given up on a key trial of one of its original lineup of innovative medicines. | Teva has given up on a key trial of ...

Tiziana Life Sciences’ intranasal drug has hit the dual endpoints of a phase 2a study in patients with a form of multiple sclerosis (MS), although the win was slightly marred by the higher dose ...

The PASI 90 rate, which is in line with the phase 2 result, looks competitive. Cross-trial comparisons can be unreliable, ...

Audax sees the propensity for IL-12 drugs to bind receptors on peripheral immune cells as a driver of the dosing and toxicity ...

The drug programs left behind after Jazz Pharmaceuticals' $820 million acquisition of Actio Biosciences have found a new home ...

Eli Lilly has dropped its phase 2 Alzheimer's disease program for mevidalen, marking another setback for the experimental ...

Eli Lilly’s triple-G drug candidate retatrutide has beaten Novo’s Ozempic in a head-to-head phase 3 trial, driving deeper ...

“If Powerful AI is directed at solving humanity’s hardest problems and the risks are managed responsibly, the potential is ...

With the U.S. patent on the immunology megablockbuster Dupixent set to expire in 2031, time is running out for Sanofi to find ...

GSK’s global restructuring plan is likely to see “some limited impact” on roles in the Big Pharma’s home turf of the U.K., ...

Every ESMO conference is eventful, but the drama kicked into gear earlier than expected this year when the eagerly ...